# Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

> **NCT00448214** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 448 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** YM150
- **DRUG:** warfarin

## Key facts

- **NCT ID:** NCT00448214
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 448 (ACTUAL)
- **Last updated:** 2011-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448214, "Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00448214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*